Vaccine News and Research

Latest Vaccine News and Research

Two new mouse models can help treat food allergies

Food allergies pose a serious and growing problem in the West. Many foods can lead to allergic reactions and this situation is further complicated by so-called cross-reactions, whereby an allergy to one particular food can trigger allergic reactions to another food. There are no treatments available for food allergies, but the establishment of two mouse models can be used to develop and test new forms of treatment, for example vaccines.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

Health care system should provide proactive interventions to prevent depression

Major depressive episodes can be prevented, and to help ensure that they are, the health care system should provide routine access to depression-prevention interventions, just as patients receive standard vaccines, according to a new article co-authored by UCSF researcher Ricardo F. Mu-oz, PhD.

15 May 2012

U.N., international community should pledge to improve water, sanitation in Haiti to mitigate cholera epidemic

"The cholera epidemic in Haiti, which began in late 2010, is bad and getting worse, for reasons that are well understood and that the aid community has done far too little to resolve," a New York Times editorial states, adding that the "Pan American Health Organization has said the disease could strike 200,000 to 250,000 people this year" and "has already killed more than 7,000."

15 May 2012

Soligenix first quarter revenues decrease to $647,418

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.

14 May 2012

Biovest plans to file BiovaxID MAA with EMA for treatment of follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest plans to file for marketing approval in the European Union (EU) for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

14 May 2012

Study reveals variability in physician intentions and recommendations on HPV vaccination

Researchers at Moffitt Cancer Center surveyed 1,008 physicians seeking their knowledge, recommendation beliefs and information on their practices regarding the controversial human papillomavirus (HPV) vaccine, which is aimed at preventing cancers resulting from sexually transmitted HPV infection. Of the physicians surveyed, 112 provided additional comments at the conclusion of the survey.

14 May 2012

JHSPH wins GCE grant for global health and development research project

The Johns Hopkins Bloomberg School of Public Health announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Alain Labrique, PhD, director of the Johns Hopkins University Global mHealth Initiative, will pursue an innovative global health and development research project, titled "mTIKKA - Harnessing a Mobile - Cloud System to Achieve Universal Vaccination."

14 May 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies.

From Cell Signaling Technology 11 May 2012

Efforts to stem childhood mortality in Ghana will not be enough to reach MDG, UNICEF official says

Anirban Chatterjee, chief of health and nutrition for UNICEF in Ghana, said the country "is doing a lot" to fight child mortality -- referring to a recently launched vaccination campaign and an initiative to educate mothers about nutrition -- but "I don't think it's enough" to reach the fourth U.N. Millennium Development Goal (MDG) to reduce the under-five mortality rate by two thirds by 2015, Inter Press Service reports.

11 May 2012

Hospital midwife inadvertently spreads whooping cough to up to 170 people

A Middlemore Hospital midwife could have infected up to 170 people with whooping cough. If passed onto babies or women in the last three months of pregnancy, the disease can lead to severe illness or even death. Whooping cough is a highly infectious disease caused by bacteria which is easily spread through coughing and sneezing, much like the common cold. Also known as pertussis, it is distinguishable by a “whooping” sound at the end of coughing attacks.

10 May 2012

Leishmaniasis vaccine trial begins in U.S., India

"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it is found most commonly in India, Nepal, Bangladesh, Brazil and Sudan," the news service notes.

10 May 2012

Georgia Tech project to design new warehousing and storage system for vaccines, drugs

The Georgia Institute of Technology has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The program funds individuals worldwide to explore ideas that can break the mold in how persistent global health and development challenges are solved.

10 May 2012

Report identifies challenges, solutions to increasing routine vaccination in Nigeria

In this post in PSI's "Healthy Lives" blog, Deputy Editor Tom Murphy examines routine vaccination solutions in Nigeria, where "the Decade of Vaccines Economics projects 90 percent vaccine coverage against Hib, pneumococcal disease, rotavirus, measles and pertussis can save 600,000 lives and $17 billion in Nigeria over the next 10 years."

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

Wan-Pei Su, a graduate student of Molecular Medicine at National Cheng Kung University (NCKU), southern Taiwan, has received a Graduate/Postdoctoral Travel Award from the American Society for Biochemistry and Molecular Biology (ASBMB) to attend the annual conference on Experimental Biology (EB) in San Diego in April 2012.

10 May 2012

IDRI, Aeras partner to develop new TB vaccine candidate

Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI's novel tuberculosis vaccine candidate. This collaboration reflects the missions of the two non-profit product development partnerships to use cutting-edge science to develop products that address critical diseases of underserved populations around the world, including tuberculosis.

10 May 2012

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.

10 May 2012